This report was first published by Endpoints News. To see the original version, click here
AbbVie is kicking off the JP Morgan Healthcare Conference with a deal in one of oncology’s hottest fields.
AbbVie announced Monday it will pay $650 million upfront to Chinese biotech RemeGen to partner on a PD-1xVEGF bispecific antibody called RC148. If all the milestones are met, AbbVie could be on the hook for as much as $4.95 billion.
您已阅读15%（428字），剩余85%（2425字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。